REFERENCES
1. Chan LL, Chan AWH, Yip TCF, et al. Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era. J Hepatol. 2025;83:1328-37.
2. Huang G, Li PP, Lau WY, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg. 2018;268:943-54.
3. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-7.
4. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229-35.
5. Xing H, Zhang WG, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB. 2020;22:677-89.
6. Zhou SL, Zhou ZJ, Song CL, et al. Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence. Signal Transduct Target Ther. 2022;7:24.
7. Li Q, Wang J, Juzi JT, et al. Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg. 2008;12:1540-7.
8. Zhang M, Chen H, Liu H, Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark Res. 2024;12:84.
9. Cho H, Ahn H, Lee DH, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. J Viral Hepat. 2018;25:707-17.
10. Choi J, Jo C, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology. 2021;73:661-73.
11. Giri S, Agrawal D, Afzalpurkar S, Gopan A, Angadi S, Sundaram S. Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: a systematic review and meta-analysis. J Viral Hepat. 2023;30:108-15.
12. Murata K, Mizokami M. Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma. J Gastroenterol Hepatol. 2023;38:683-91.
13. Linye H, Zijing X, Xiaoyun Z, Zhihui L, Tianfu W, Chuan L. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial. Int J Surg. 2023;109:3032-41.
14. Lumley SF, Delphin M, Mokaya JF, et al. A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir. J Clin Virol. 2024;174:105711.
15. Akabane M, Kawashima J, Altaf A, et al. Enhancing recurrence-free survival prediction in hepatocellular carcinoma: a time-updated model incorporating tumor burden and AFP dynamics. Ann Surg Oncol. 2025;32:5648-56.
16. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
17. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
18. Fu Y, Li X, Yang Z, et al. A risk-based postresection follow-up strategy for hepatocellular carcinoma patients. Cancer. 2023;129:569-79.
19. Rich NE, Singal AG. Direct-acting antiviral therapy and hepatocellular carcinoma. Clin Liver Dis. 2021;17:414-7.
